Clinical trials: Atopic Hypersensitivity
Cutaneous T-cell Lymphoma, Sezary Syndrome
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema
- Trial name
- NCT00177268
- Testing
- Blood draw, skin biopsy or urine collection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Atopic Dermatitis
Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
This study is designed to determine whether the addition of topical Altabax (R) to a treatment regimen of topical corticosteroid therapy speeds clearance of atopic dermatitis and improves quality of life.
- Trial name
- NCT00871208
- Testing
- Altabax (R), Vehicle and Locoid lipocream (R)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Eczema, Dermatitis
Effects of Treatments on Atopic Dermatitis
Background: Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria.
- Conditions
- Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic
- Trial name
- NCT01631617
- Testing
- Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
- Trial name
- NCT03517566
- Testing
- ZPL389 3mg, ZPL389 10mg, ZPL389 30mg
- Where
- 89 sites in United States, Austria and 14 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Global Healthcare Study on Atopic Dermatitis
The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and…
- Trial name
- GHSAD (NCT07659756)
- Where
- Switzerland
- Volunteers
- 9,600 people
- Sponsor
- Julia Tatjana Maul
Atopic Dermatitis
Apremilast for Atopic Dermatitis - A Pilot Study in Adults
The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.
- Trial name
- NCT01393158
- Testing
- Apremilast
- Volunteers
- 16 people
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis
Tralokinumab for Dupilumab Failures
24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.
- Trial name
- NCT06773455
- Testing
- tralokinumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Atopic Dermatitis
Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age
Atopic dermatitis (AD) is an frequent chronic and itchy inflammatory dermatitis which concern about 20% of pediatric population with a revelation usually toward 3-6 months of live.
- Trial name
- PRURINEO (NCT03684343)
- Testing
- Filmed consultation with a dermatologist
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Atopic Dermatitis
Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin
Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with…
- Trial name
- NCT03484897
- Testing
- P927 - LICHTENA DermAD CREMA CORPO
- Where
- Italy
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Derming SRL
Atopic Dermatitis
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for…
- Trial name
- NCT07629778
- Testing
- HL-300
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
- Trial name
- D2213C00001 (NCT02347176)
- Testing
- Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 204 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.
The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.
- Trial name
- NCT06553287
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, LNK01004 ointment 1.5%
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Type I Hypersensitivity
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated.
- Trial name
- NCT00109759
- Testing
- RagweedMATAMPL
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are…
- Trial name
- GECKO (NCT03864627)
- Testing
- MOR106
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with…
- Trial name
- NCT06956196
- Testing
- Stapokibatrt
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Keymed Biosciences Co.Ltd
Allergy to House Dust, Allergy Pollen
Validation and Reproducibility of S.P.A.T. With Allergens
To improve accuracy and take out human error opportunities, Hippo Dx developed S.P.A.T., an automated skin prick test. This study will provide a comparison between manual and automated skin prick test in allergic and non-allergic…
- Trial name
- NCT05824637
- Testing
- Skin Prick Automated Test, Skin Prick Manual Test
- Where
- Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hippocreates
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Atopic Dermatitis
Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis, which is also known as atopic eczema, is a common inflammatory and chronic skin disease that is characterized by severe recurrent erythematous and pruritic lesions.
- Trial name
- NCT05969730
- Testing
- Baricitinib 4 MG, Azathioprine 1.5-2.5 mg/kg
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Mazandaran University of Medical Sciences
Atopic Dermatitis (AD)
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500.
- Trial name
- NCT06923228
- Testing
- CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- CAGE Bio Inc.